Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Infusion Rate of Amino Acids in Head and Neck Cancer
NCT01923480Phase 4Terminated
- Sponsor
- Baxter
- Start
- Jul 2013
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of clinisol in head and neck cancer (HNC), sponsored by Baxter. Started Jul 2013; status: terminated.
02
Drugs
clinisol
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT01923480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01923480.